These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

507 related articles for article (PubMed ID: 23881169)

  • 1. Erythropoietin is involved in the angiogenic potential of bone marrow macrophages in multiple myeloma.
    De Luisi A; Binetti L; Ria R; Ruggieri S; Berardi S; Catacchio I; Racanelli V; Pavone V; Rossini B; Vacca A; Ribatti D
    Angiogenesis; 2013 Oct; 16(4):963-73. PubMed ID: 23881169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rhu-Epo down-regulates pro-tumorigenic activity of cancer-associated fibroblasts in multiple myeloma.
    Desantis V; Frassanito MA; Tamma R; Saltarella I; Di Marzo L; Lamanuzzi A; Solimando AG; Ruggieri S; Annese T; Nico B; Vacca A; Ribatti D
    Ann Hematol; 2018 Jul; 97(7):1251-1258. PubMed ID: 29589107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of erythropoietin in the angiogenic activity of bone marrow endothelial cells of MGUS and multiple myeloma patients.
    Lamanuzzi A; Saltarella I; Ferrucci A; Ria R; Ruggieri S; Racanelli V; Rao L; Annese T; Nico B; Vacca A; Ribatti D
    Oncotarget; 2016 Mar; 7(12):14510-21. PubMed ID: 26919105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma.
    Vacca A; Ribatti D; Presta M; Minischetti M; Iurlaro M; Ria R; Albini A; Bussolino F; Dammacco F
    Blood; 1999 May; 93(9):3064-73. PubMed ID: 10216103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The erythropoietin receptor and its expression in tumor cells and other tissues.
    Farrell F; Lee A
    Oncologist; 2004; 9 Suppl 5():18-30. PubMed ID: 15591419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma.
    Ribatti D; Vacca A; Nico B; Quondamatteo F; Ria R; Minischetti M; Marzullo A; Herken R; Roncali L; Dammacco F
    Br J Cancer; 1999 Feb; 79(3-4):451-5. PubMed ID: 10027312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The hypoxia inducible factor/erythropoietin (EPO)/EPO receptor pathway is disturbed in a rat model of chronic kidney disease related anemia.
    Landau D; London L; Bandach I; Segev Y
    PLoS One; 2018; 13(5):e0196684. PubMed ID: 29738538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pentraxin 3 (PTX3) inhibits plasma cell/stromal cell cross-talk in the bone marrow of multiple myeloma patients.
    Basile A; Moschetta M; Ditonno P; Ria R; Marech I; De Luisi A; Berardi S; Frassanito MA; Angelucci E; Derudas D; Specchia G; Curci P; Pavone V; Rossini B; Ribatti D; Bottazzi B; Mantovani A; Presta M; Dammacco F; Vacca A
    J Pathol; 2013 Jan; 229(1):87-98. PubMed ID: 22847671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erythropoietin (EPO)-receptor signaling induces cell death of primary myeloma cells in vitro.
    Våtsveen TK; Sponaas AM; Tian E; Zhang Q; Misund K; Sundan A; Børset M; Waage A; Brede G
    J Hematol Oncol; 2016 Aug; 9(1):75. PubMed ID: 27581518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.
    Di Raimondo F; Azzaro MP; Palumbo G; Bagnato S; Giustolisi G; Floridia P; Sortino G; Giustolisi R
    Haematologica; 2000 Aug; 85(8):800-5. PubMed ID: 10942925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erythropoietin-induced activation of the JAK2/STAT5, PI3K/Akt, and Ras/ERK pathways promotes malignant cell behavior in a modified breast cancer cell line.
    Shi Z; Hodges VM; Dunlop EA; Percy MJ; Maxwell AP; El-Tanani M; Lappin TR
    Mol Cancer Res; 2010 Apr; 8(4):615-26. PubMed ID: 20353997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression.
    Kumar S; Witzig TE; Timm M; Haug J; Wellik L; Kimlinger TK; Greipp PR; Rajkumar SV
    Blood; 2004 Aug; 104(4):1159-65. PubMed ID: 15130943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erythropoietin is involved in growth and angiogenesis in malignant tumours of female reproductive organs.
    Yasuda Y; Fujita Y; Masuda S; Musha T; Ueda K; Tanaka H; Fujita H; Matsuo T; Nagao M; Sasaki R; Nakamura Y
    Carcinogenesis; 2002 Nov; 23(11):1797-805. PubMed ID: 12419827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erythropoietin priming improves the vasculogenic potential of G-CSF mobilized human peripheral blood mononuclear cells.
    Kang J; Yun JY; Hur J; Kang JA; Choi JI; Ko SB; Lee J; Kim JY; Hwang IC; Park YB; Kim HS
    Cardiovasc Res; 2014 Oct; 104(1):171-82. PubMed ID: 25082847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human erythropoietin increases the pro-angiogenic potential of A2780 ovarian adenocarcinoma cells under hypoxic conditions.
    Kriška J; Solár P; Varinská L; Solárová Z; Kimáková P; Mojžiš J; Fedoročko P; Sytkowski AJ
    Oncol Rep; 2013 Sep; 30(3):1455-62. PubMed ID: 23807540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. β Common receptor integrates the erythropoietin signaling in activation of endothelial nitric oxide synthase.
    Su KH; Shyue SK; Kou YR; Ching LC; Chiang AN; Yu YB; Chen CY; Pan CC; Lee TS
    J Cell Physiol; 2011 Dec; 226(12):3330-9. PubMed ID: 21321940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Src transduces erythropoietin-induced differentiation signals through phosphatidylinositol 3-kinase.
    Kubota Y; Tanaka T; Kitanaka A; Ohnishi H; Okutani Y; Waki M; Ishida T; Kamano H
    EMBO J; 2001 Oct; 20(20):5666-77. PubMed ID: 11598010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo angiogenic activity of erythropoietin.
    Ribatti D
    Methods Mol Biol; 2013; 982():227-35. PubMed ID: 23456873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does erythropoietin have a dark side? Epo signaling and cancer cells.
    Sytkowski AJ
    Sci STKE; 2007 Jul; 2007(395):pe38. PubMed ID: 17636183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pigment epithelium-derived factor inhibits erythropoietin-induced retinal endothelial cell angiogenesis by suppression of PI3K/Akt pathway.
    Haribalaganesh R; Sheikpranbabu S; Banumathi E; Gurunathan S
    Exp Eye Res; 2010 Jun; 90(6):726-33. PubMed ID: 20298690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.